Bank of New York Mellon Corp Buys 35,634 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

Bank of New York Mellon Corp boosted its stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 72.5% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 84,762 shares of the company’s stock after buying an additional 35,634 shares during the period. Bank of New York Mellon Corp owned approximately 0.17% of Mineralys Therapeutics worth $992,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. Catalys Pacific LLC bought a new position in shares of Mineralys Therapeutics during the fourth quarter valued at $79,073,000. RA Capital Management L.P. raised its holdings in Mineralys Therapeutics by 52.6% in the first quarter. RA Capital Management L.P. now owns 4,850,984 shares of the company’s stock worth $62,626,000 after buying an additional 1,672,508 shares during the last quarter. SR One Capital Management LP lifted its stake in shares of Mineralys Therapeutics by 12.4% in the first quarter. SR One Capital Management LP now owns 2,016,822 shares of the company’s stock worth $26,037,000 after buying an additional 222,222 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Mineralys Therapeutics by 0.5% in the first quarter. Vanguard Group Inc. now owns 982,932 shares of the company’s stock worth $12,690,000 after buying an additional 4,952 shares in the last quarter. Finally, Franklin Resources Inc. increased its position in shares of Mineralys Therapeutics by 55.4% during the fourth quarter. Franklin Resources Inc. now owns 699,467 shares of the company’s stock valued at $6,015,000 after acquiring an additional 249,450 shares in the last quarter. Hedge funds and other institutional investors own 84.46% of the company’s stock.

Insider Buying and Selling at Mineralys Therapeutics

In other news, CFO Adam Scott Levy sold 10,757 shares of the firm’s stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $13.14, for a total value of $141,346.98. Following the transaction, the chief financial officer now directly owns 247,611 shares in the company, valued at approximately $3,253,608.54. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, CFO Adam Scott Levy sold 10,757 shares of the company’s stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $13.14, for a total transaction of $141,346.98. Following the completion of the sale, the chief financial officer now owns 247,611 shares of the company’s stock, valued at approximately $3,253,608.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Brian Taylor Slingsby sold 550,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 24th. The stock was sold at an average price of $13.05, for a total transaction of $7,177,500.00. Following the completion of the transaction, the director now directly owns 8,644,579 shares in the company, valued at approximately $112,811,755.95. The disclosure for this sale can be found here. In the last ninety days, insiders sold 577,028 shares of company stock worth $7,536,774. Insiders own 33.24% of the company’s stock.

Mineralys Therapeutics Stock Performance

Shares of NASDAQ:MLYS opened at $11.71 on Friday. The firm has a market cap of $581.39 million, a price-to-earnings ratio of -5.35 and a beta of 1.93. The business has a 50-day simple moving average of $12.01 and a two-hundred day simple moving average of $12.46. Mineralys Therapeutics, Inc. has a fifty-two week low of $5.85 and a fifty-two week high of $16.91.

Mineralys Therapeutics (NASDAQ:MLYS) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.10). During the same quarter in the previous year, the firm earned ($0.31) EPS. As a group, research analysts predict that Mineralys Therapeutics, Inc. will post -3.08 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Mineralys Therapeutics in a research note on Thursday, August 15th.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.